Go Pro
NASDAQ:ASMB

Assembly Biosciences Q2 2026 Earnings Report

Assembly Biosciences logo
$23.66 -0.31 (-1.29%)
Closing price 09/24/2026 04:00 PM Eastern
Extended Trading
$23.63 -0.03 (-0.13%)
As of 09/24/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Assembly Biosciences EPS Results

Actual EPS
-$0.20
Consensus EPS
-$0.72
Beat/Miss
Beat by +$0.52
One Year Ago EPS
N/A

Assembly Biosciences Revenue Results

Actual Revenue
$13.37 million
Expected Revenue
$8.60 million
Beat/Miss
Beat by +$4.78 million
YoY Revenue Growth
N/A

Assembly Biosciences Announcement Details

Quarter
Q2 2026
Time
After Market Closes
Conference Call Date
Thursday, August 13, 2026
Conference Call Time
7:00AM ET

Upcoming Earnings

Assembly Biosciences' Q3 2026 earnings is estimated for Monday, November 9, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 6, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Assembly Biosciences Earnings Headlines

Assembly Biosciences (ASMB) Receives a Buy from Mizuho Securities
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.tc pixel
See More Assembly Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Assembly Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Assembly Biosciences and other key companies, straight to your email.

About Assembly Biosciences

Assembly Biosciences (NASDAQ:ASMB) is a clinical-stage biotechnology company developing oral therapies for serious viral infections. Its research programs have focused primarily on chronic hepatitis B virus (HBV) infection and herpesvirus diseases, with the goal of addressing areas where existing treatments may not provide a functional cure or durable disease control.

The company’s pipeline includes investigational HBV capsid assembly modulators, including ABI-4334, designed to interfere with key stages of the HBV lifecycle. Assembly is also developing antiviral candidates for herpes simplex virus (HSV), including ABI-5366, a long-acting helicase-primase inhibitor intended to prevent viral replication. These programs remain investigational and are subject to clinical and regulatory evaluation.

Assembly Biosciences has historically advanced its programs through a combination of internal research and strategic collaboration. The company entered into a collaboration with Gilead Sciences covering certain HBV research and development activities. Assembly is led by William M. Collier, who serves as president and chief executive officer.

View Assembly Biosciences Profile